<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605095</url>
  </required_header>
  <id_info>
    <org_study_id>5/2018</org_study_id>
    <nct_id>NCT03605095</nct_id>
  </id_info>
  <brief_title>Evidence of Spreading Vasodilation in Human Gingiva</brief_title>
  <official_title>Non-invasive Imaging of Human Gingival Microcirculation: Effect of Nitric Oxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to observe the mechanism of spreading vasodilatation on human
      healthy gingiva. Nitric-oxide donor solutions in lower and higher concentration are used to
      trigger the vasoactivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spatial regulation of gingival microcirculation has not been revealed yet. Although this
      could be an important mechanism to protect gingiva as it is exposed to mechanical, chemical,
      thermal etc. irritation during whole life. It is especially important during flap surgery.
      Laser Speckle Contrast Imaging (LSCI) is novel non-invasive method with high spatio-temporal
      resolution, therefore it allows us to study remote effect of local vasodilation such as
      spreading vasodilation in human gingiva.

      The vasodilatator nitric-oxide (NO) donor will be used to trigger remote effect on gingiva.
      NO donor solutions will be applied in 1 mg/ml and 8 mg/ml nitroglycerin concentrations.
      Solution will be dropped on the gingiva at tooth 12 in a fabricated leakage proof well
      attached to 2mm above the marginal gingiva. The change on blood flow will be monitor at the
      test well with surrounding gingival area spanning 3 tooth and at the contralateral side by
      LSCI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow change after application of NO agonist</measure>
    <time_frame>30 min</time_frame>
    <description>The change in blood flow will be measured after locally applied nitroglycerin at the site fo application and at the remote sites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparsion of the change in blood flow between genders</measure>
    <time_frame>30min</time_frame>
    <description>The maximal blood flow changed assessed in primary outcome will be split into two groups based on gender. The change will be compared between males and females.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the change in blood flow and gingival thickness</measure>
    <time_frame>30min</time_frame>
    <description>The biotpye will be assessed by measurement of gingival thickness by an ultrasonic devices. The correlation between thickness and maximal vasodilation will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Nitric Oxide</condition>
  <condition>Vasodilation</condition>
  <condition>Oral Soft Tissue Conditions</condition>
  <arm_group>
    <arm_group_label>8 mg/ml nitroglycerin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Higher concentration of NO donor (Nitromint) vs dilution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/ml nitroglycerin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lower concentration of NO donor (Nitropohl) vs physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitroglycerin</intervention_name>
    <description>Vasodilatator solution is dropped on the gingiva.</description>
    <arm_group_label>1 mg/ml nitroglycerin</arm_group_label>
    <arm_group_label>8 mg/ml nitroglycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  general health

          -  minimum 5 mm keratinized gingiva at upper front teeth

        Exclusion Criteria:

          -  pregnancy and breast-feeding

          -  medication (except contraceptives)

          -  smoking

          -  periodontitis

          -  caries

          -  insufficient marginal integrity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Janos Vag</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Dr. Vag Janos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>spreading vasodilation</keyword>
  <keyword>gingival microcirculation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

